Osimertinib Plus Chemo Ups PFS, Toxicity in First Line Osimertinib Plus Chemo Ups PFS, Toxicity in First Line
Combining osimertinib with chemotherapy improved progression-free survival in EGFR-mutated non-small cell lung cancer, new interim data show, but experts have raised concerns about toxicity.Medscape Medical News
Source: Medscape Pathology Headlines - Category: Pathology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Hematology | Lung Cancer | Non-Small Cell Lung Cancer | Pathology | Toxicology